Gennova Biopharmaceuticals launches paediatric pack size of HAMSYL Junior

Pune: Gennova Biopharmaceuticals Ltd announces the launch of paediatric pack size of pegaspargase, HAMSYL Junior, which will now be available in a 1500 IU pack size. This advances healthcare for Indian children suffering from an orphan disease called acute lymphoblastic leukaemia (ALL), a rare and challenging form of blood cancer primarily affecting children. An orphan disease, in medical terms, is a condition that impacts a small population, making research and development challenging.

With a 1500 IU pack size and a 2.0 mL fill volume, HAMSYL Junior ensures optimal dosing while retaining the same API strength (750 IU/mL), marking a significant stride in providing paediatric patients in India with a specifically designed and accessible treatment.

Speaking on the launch, Dr Sanjay Singh, CEO, Gennova Biopharma Limited, said, "With the launch of HAMSYL Junior, we triumph over cost barriers, advancing ALL management in line with global standards. This launch marks a pivotal step in our mission to democratise healthcare, ensuring universal access and responsiveness to diverse patient needs."